BHI Therapeutic Sciences Jamaica provides access to stem cell therapies to patients who may benefit from these treatments. We engage in collaborative relationships with leading institutions, scientists, and physicians across the globe.
We only utilize stem cells from either your own body (autologous) or from umbilical cord donors who have proceeded through a multiple step testing process that ensures stem cell patient safety. We do not use embryonic stem cells, nor will we ever.
BHI Therapeutic Sciences Jamaica has US board-certified physicians on staff for your safety. Our Scientific Advisory Board and Ethics Committee oversee the disease-specific protocols to ensure the highest standards of patient safety.
BHI Therapeutic Sciences Jamaica provides therapies for neurologic disorders, autoimmune diseases, and orthopedics conditions.
Hundreds of allogeneic stem cell therapies are underway in humans for a wide-range of medical conditions. However, some of these studies do not follow regulatory compliances and accordingly they have not been proven to be safe. The human Umbilical Cord Blood products that have been evaluated in clinical studies conducted by BHITS were collected in accordance with Good Tissue Practice to ensure the safety of the administered cellular product. BHITS has unique advantages over its competitors. We are in regulatory compliance in each country we conduct clinical trials to ensure the lab and clinical procedures are lawfully approved by their federal agencies. Based on our nonclinical and pilot clinical study results, showing the safety of our human umbilical cord blood product, we are planning to start Investigational New Drug (IND) clinical trials. We are initiating an IND Phase 1 clinical trial of an FDA approved HCP, cord blood product for acute ischemic stroke indication. In specific markets around the world, there is both the unmet need and the financial opportunity to establish medical facilities that provide the same quality as that found in the best facilities in the United States. BHITS believes it is uniquely positioned to become a leader in providing the highest quality cellular therapies through centers it intends to locate throughout the world. BHITS has recruited top medical professionals and scientific advisors, and regulatory specialists to help determine the best possible procedures to offer, to provide the appropriate protocols to monitor safety and efficacy, to collect and analyze outcome data for potential submission to the FDA and EMA, and to innovate patent procedures, devices, and therapies for future commercialization.